CHRS - Coherus ends Junshi-partnered TIGIT Program in portfolio shakeup
2024-01-10 07:24:49 ET
More on Coherus BioSciences
- Coherus BioSciences Is A Buy On The Dip After Toripalimib Approval
- Coherus: The Surface Acquisition Is A Distraction
- Coherus BioSciences, Inc. (CHRS) Q3 2023 Earnings Call Transcript
- Coherus gets FDA approval for new Udenyca delivery system, stock +24% after hours
- Coherus cancer drug undercuts Merck's Keytruda
For further details see:
Coherus ends Junshi-partnered TIGIT Program in portfolio shakeup